Compare BioNTech SE - ADR (BNTX) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Levi Strauss & Co. — how do they compare? BioNTech SE - ADR trades at $90.53 (market cap $23.31B), while Levi Strauss & Co. trades at $22.69 (market cap $9.09B). The key difference: BioNTech SE - ADR is far larger — about 2.6× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 2.71% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | LEVI | |
|---|---|---|
Market Cap | $23.31B | $9.09B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $25.53 |
52-Week Low | $83.89 | $17.92 |
Enterprise Value | $6.60B | $10.40B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
Levi Strauss (LEVI) trades at $24.4, up 0.39% on the day, with a bullish fundamental backdrop including strong earnings beats and a 77.78% analyst buy rating. The stock shows a bearish technical signal overall, with neutral RSI readings and key resistance at $25. Recent news highlights a cybersecurity breach disclosed on August 7, 2026, but the company's direct-to-consumer digital strategy continues to drive growth.
Outlook remains positive with a consensus price target of $27.88, implying 14.3% upside, supported by robust profitability and raised 2026 guidance. Risks include recent cybersecurity issues, tariff pressures, and execution challenges in a competitive apparel market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
